US Patent

US9763954 — Therapeutical uses of eslicarbazepine

Method of Use · Assigned to Bial Portela and Cia SA · Expires 2028-09-13 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects new therapeutic uses of eslicarbazepine and eslicarbazepine acetate for treating intractable conditions.

USPTO Abstract

New applications of eslicarbazepine and eslicarbazepine acetate in the treatment of intractable conditions.

Drugs covered by this patent

Aptiom (ESLICARBAZEPINE ACETATE) · Sumitomo Pharma Am

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2123`	—	Aptiom
`U-2123`	—	Aptiom
`U-2123`	—	Aptiom
`U-2123`	—	Aptiom

Patent Metadata

Patent number: US9763954
Jurisdiction: US
Classification: Method of Use
Expires: 2028-09-13
Drug substance claim: No
Drug product claim: No
Assignee: Bial Portela and Cia SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.